Author Cases with CD4 < 200 (% of total PLWH in study) Severe Manifestations Suspected IRIS (%) Time to initiation of ART (median days) Mortality among PLWH CD4 < 200 (%) Median Days to death after diagnosis Notes
Mitja et al 179 (85%) Necrotizing Skin Lesions, lung involvement, CNS involvement, GI involvement, secondary infections, sepsis 21 (25%) 21 27 (15%) 47 57% mortality rate of those with suspected IRIS.
Triana-Gonzalez et al 10 (15.6) Intestinal obstruction/peritonitis, lung involvement/ARDS, Not provided Not provided 4 (40%) 50 Risk factors for mortality: CD4 < 100, absence of ART, >50 lesions at presentation.
Miller et al 40 (93%) Necrotizing Skin lesions, lung involvement, CNS involvement, Not provided Not provided Not provided Not provided Advocates combining anti-MPXV therapies with progression.
Riser et al
24 (89%)
Necrotizing skin lesions
24 (89%)
15
24 (100%) *Only included deceased
68
23 of the 27 HIV+ patients had CD4 counts < 50
Hermanussen et al 4 Necrotizing skin lesions, deep soft tissue abscess/myositis, GI involvement, CNS involvement 0 Not provided NA NA All patients treated with tecovirimat. Those with CD4 < 200 hospitalized > 2 weeks.
Warner et al 2 (100%) Necrotizing skin lesions, CNS involvement, septic arthritis, secondary infections, sepsis 2 (100%) 33 1 (50%) 68 Both patients with suspected IRIS.
Pettit et al 2 Necrotizing skin lesions, GI involvement, pulmonary involvement, bacterial superinfection 2 (100%) Not provided 2 (100%) 35 Both patients with suspected IRIS, treated with steroids and pausing of ART.
Filippov et al 1 Necrotizing skin lesions, lung involvement, ocular involvement Never on ART Never on ART 1 74 Patient declined ART, was treated with cidofovir, tecovirimat and VIGIV.
Stafford et al 1 Necrotizing skin and oral lesions 0 immediate NA NA Patient treated with ART, tecovirimat and cidofovir.
Viguier et al 1 Necrotizing skin lesions 0 47 NA NA
Thet et al 1 Necrotizing skin lesions, GI involvement, bacterial superinfection 1 immediate NA NA Patient treated with ART, tecovirimat, and VIGIV. Recovery did not begin until after VIGIV administration.
Caria et al 1 Necrotizing skin lesions, GI involvement, lung involvement, CNS involvement 1 46 1 (100%) 107 Patient treated with ART, tecovirimat, and cidofovir.
Martinez et al
0 *Case had CD4 count of 218 cells/mm3
Necrotizing skin lesions, GI involvement, rectal abscess, bacterial superinfection
1
Not provided
NA
NA
Patient treated with ART, tecovirimat, cidofovir and VIGIV.